003520 — Yungjin Pharm Co Balance Sheet
0.000.00%
- KR₩370bn
- KR₩432bn
- KR₩252bn
- 62
- 10
- 13
- 15
Annual balance sheet for Yungjin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 428 | 465 | 682 | 10,208 | 3,436 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 45,012 | 48,145 | 51,551 | 52,826 | 47,187 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 98,675 | 89,688 | 102,194 | 126,564 | 123,818 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 75,779 | 88,435 | 85,640 | 85,319 | 98,013 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 188,101 | 194,095 | 203,083 | 226,601 | 234,258 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30,140 | 48,329 | 49,632 | 75,055 | 114,634 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 73,669 | 89,210 | 113,213 | 136,968 | 144,455 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 114,432 | 104,885 | 89,870 | 89,632 | 89,803 |
Total Liabilities & Shareholders' Equity | 188,101 | 194,095 | 203,083 | 226,601 | 234,258 |
Total Common Shares Outstanding |